DS3790 / Daiichi Sankyo - LARVOL DELTA

A Phase 1/2, First-in-Human, Multicenter Study of DS3790, a CD37-Directed DXd Antibody-Drug Conjugate, in Patients With B-Cell Non-Hodgkin Lymphoma (SOHO 2026) - P1/2 | "Additionally, efficacy by CR is a secondary end point for dose escalation and dose expansion. B-NHL: B-cell non-Hodgkin lymphoma; CR: complete response; DXd: an exatecan derivative; ECOG PS: Eastern Cooperative Oncology Group performance status; RP2D: recommended phase 2 dose."

ADC • Clinical • First-in-human • P1/2 data • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • CD37

DS3790-076: A First-in-Human Trial of DS3790a in Participants with Hematological Malignancies. (clinicaltrialsregister.eu) - P1/2 | N=30 | Not yet recruiting | Sponsor: Daiichi Sankyo Inc.

First-in-human • New P1/2 trial • Hematological Malignancies • Oncology

The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. (Businesswire) - "The trial is expected to enroll approximately 420 patients across multiple sites globally, including Asia, Europe and North America."

First-in-human • Trial status • Non-Hodgkin’s Lymphoma

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies (clinicaltrials.gov) - P1/2 | N=420 | Recruiting | Sponsor: Daiichi Sankyo | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Hematological Malignancies • Oncology